Is Once-Daily Kaletra an Effective Dosing Option?
An international study comparing Norvir (ritonavir)-boosted Prezista (darunavir) to Kaletra (lopinavir/ritonavir) in people starting treatment for the first time has reported a surprising secondary finding—better virologic control among patients with high pre-therapy viral loads using twice daily, as opposed to once daily, Kaletra.

Strategies for Success With Kaletra Monotherapy
Two reports regarding the experimental use of Kaletra (lopinavir/ritonavir), without other medications, show that it can successfully keep HIV under control, and offer predictions regarding who will most likely benefit from the use of Kaletra monotherapy.

Rilpivirine Comparable to Sustiva in Treatment First-TimersThe experimental non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine is comparable to Sustiva in terms of reducing HIV levels and increasing CD4 counts over 48 weeks in people taking antiretroviral treatment for the first time.

October 31, 2007

HIV Treatment Greatly Improves Brain Illness SurvivalCombination antiretroviral (ARV) treatment has significantly increased survival in people diagnosed with AIDS-related illnesses of the brain, according to data presented at the 11th European AIDS Conference in Madrid.

October 27, 2007

Crestor Bests Pravachol for Elevated LipidsCrestor is superior to Pravachol in HIV-positive people on antiretroviral therapy who experience LDL cholesterol and triglyceride elevations, according to new data presented at the 11th EACS in Madrid.

Tesamorelin (TH9507) Safe and Effective for 52 WeeksHIV-positive patients with lipodystrophy can be treated safely and effectively with tesamorelin (TH9507) for at least 52 weeks, according to new data presented this week at the 11th European AIDS Conference in Madrid.

October 29, 2007

Small Steps Forward in HIV PreventionSlow but steady progress is being made on several HIV prevention fronts, say researchers in a special symposium on HIV prevention at the 11th European AIDS Conference.

-->

October 27, 2007

New Menu of Antiviral OptionsDr. José Gatell talks with David Evans about the latest treatment news on Selzentry, rilpivirine (TMC278) and the continued interest in Kaletra monotherapy.

Children and Challenges: Treating Pediatric HIVOver 2 million children are living with HIV/AIDS throughout the world. Dr. José Ramos talks with Peter Staley about the unique challenges facing HIV-positive children and their health care providers.